Analyst Research Report Snapshot

Title:

BIOINVENT INTERNATIONAL - GAINING THE MILESTONES ON THE ROAD TO RECOVERY

Price:

$10.00

Provider:

Edison Investment Research

Date:

26 Feb 2014

Pages:

2

Type:

AcrobatPDF

Companies referenced:

BINV.ST

Available for Immediate Download
Summary:

Revenues for FY13 were SEK81.7m with a Q4 profit due to a milestone from Bayer. The loss was SEK18m with December net cash of SEK65m before the announced March capital-raising of SEK64m. BioInvent now appears well placed to grow its revenues and the pipeline is being rebuilt. BI-505 should produce Phase IIa data in Q314 and BI 1206 may enter trials in late 2014. Good preclinical data on both candidates may gain partnering deals and upfront fees. The pipeline of collaborations based on the n-CoDeR library and F.I.R.S.T technology looks strong.

Why buy analyst research?

  • Institutional quality research
  • Available for Immediate Download
  • Detailed company or industry insight
  • Print or save
  • 24 hour customer support
Return to previous page without adding this item to your cart.
Email Customer Support.

About Analyst Research

Analyst research reports are available for immediate download after purchase. You will have unlimited access to the report for 24 hours after purchase, to download, print or save it as many times as you wish. Analyst Research provided by Reuters does not constitute investment advice, and is not endorsed by Reuters Research. This information is protected by copyright and intellectual property laws. More information on Analyst Research.